We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HSP-90 inhibitors promise to complement cancer therapies.
- Authors
Vastag, Brian
- Abstract
The article reports that Hayward, California-based Kosan Biosciences and Manchester, England-based NeuTec Pharma will begin pivotal clinical trials of drugs that will inhibit heat shock protein 90, a molecule abundant in tumors and fungal infections. These drugs could prove a significant complement to existing cancer therapies. Kosan is developing drugs targeted specifically against cancer, while NeuTec is developing drugs to fight fungal infections with cancer as a secondary target.
- Subjects
KOSAN Biosciences Inc.; NEUTEC Pharma PLC; CLINICAL trials; ANTINEOPLASTIC agents; ANTIFUNGAL agents
- Publication
Nature Biotechnology, 2006, Vol 24, Issue 11, p1307
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt1106-1307